Prothrombin coagulation disorders

Congenital deficiency of prothrombin is inherited in an autosomal recessive fashion and is the rarest of all the hereditary coagulation disorders. Congenital dysprothrombinemia has also been recognized. 

Coagulation disorders Elevated prothrombin time, partial thromboplastin time, D-dimers hypofibrinogenemia... 

The hematological effects of tumor necrosis factor alfa mostly consist of dose-related thrombocytopenia and granulocytopenia, and decreased monocyte or lymphocyte counts (SED-13, 1111) (11,12). Septic episodes are sometimes associated with leukopenia. Coagulopathy with laboratory evidence of disseminated intravascular coagulopathy was found in 30% of patients and was sometimes associated with thromboembolic events (13). Other coagulation disorders include transient alterations in prothrombin time, and a rise in the plasma concentrations of von Willebrand factor was found in healthy volunteers (14). 

Coagulation disorders Blood products (PPF, platelets), vitamin K CBC, prothrombin time, platelet count Normalize PT time, maintain/improve hemostasis... 

Phytonadione is a blood modifier/vitamin K. It promotes hepatic synthesis of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX) and Stuart factor (factor X). It is indicated in the management of coagulation disorders due to faulty formation of factors II, Vn, IX, and X due to vitamin K deficiency or interference with vitamin K activity. Oral/parenteral used for treatment of anticoagulant-induced prothrombin deficiency treatment of hypoprothrombinemia secondary to salicylates or antibacterial therapy, or secondary to obstructive jaundice and biliary fistulas, provided bile salts are also given. Parenteral used for treatment of hypoprothrombinemia secondary to conditions limiting absorption or synthesis of vitamin K prophylaxis and therapy of hemorrhagic disease of the newborn. 

Ofloxacin 200 mg daily for 7 days did not signifrcantly affect the prothrombin times of 7 healthy subjects stabilised on phenprocoumon. In a population-based cohort study, there were no cases of over-anticoagu-lation (USTR greater than 6) in patients taking acenocoumarol or phenprocoumon with ofloxacin (33 received ofloxacin. Note that this study did find an increased risk for norfloxacin, see (j) above. Furthermore, for the period December 1990 to January 2004, Health Canada had not received any reports of suspected coagulation disorders associated with ofloxacin and warfarin. ... 

In a prospective study of 23 children several coagulation disorders were associated with valproate thrombocytopenia n = 2), acquired von Willebrand s disease (6), a significant fall in fibrinogen concentrations (12), and a reduction in factor XIII (4) [373 ]. Thrombelastography showed altered platelet function in 11 and prothrombin time was significantly prolonged, with many other coagulation defects. 

Isshiki I, Murata M, Watanabe R, Matsubara Y, Kawano K, Aoki N, et al. Frequencies of prothrombin 2021OG-A mutation may be different among races-studies on Japanese populations with various forms of thrombotic disorders and healthy subjects. Blood Coagul Fibrinol 1998 9 105-6. 

---